News | June 11, 2024
Abbott wins CE mark for dual-chamber leadless pacemaker
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine
ALS is a rare, progressive and fatal neurodegenerative disease, with an average life expectancy of 3 to 5 years from the time of symptom onset
Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%
If approved in the European Union, Fruquintinib will be the first novel targeted therapy for Metastatic Colorectal Cancer regardless of biomarker status in over a decade
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
Subscribe To Our Newsletter & Stay Updated
